派格生物医药-B(02565)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02565 派格生物医药-B

休市中 12-05 16:09:08

62.900

-1.650

-2.56%

最高64.700	最低62.650	成交量23.80万
今开64.550	昨收64.550	日振幅3.18%
总市值242.79亿	流通市值175.59亿	总股本3.86亿
成交额1,514万	换手率0.09%	流通股本2.79亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02565","market":"HK","secType":"STK","nameCN":"派格生物医药-B","latestPrice":62.9,"timestamp":1764922148006,"preClose":64.55,"halted":0,"volume":238000,"delay":0,"floatShares":279164339,"shares":386000000,"eps":-0.8501952592785752,"marketStatus":"休市中","change":-1.65,"latestTime":"12-05 16:09:08","open":64.55,"high":64.7,"low":62.65,"amount":15141600,"amplitude":0.031758,"askPrice":63,"askSize":3000,"bidPrice":62.7,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-0.661447082946726,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":7,"adr":0,"listingDate":1748275200000,"exchange":"SEHK","adjPreClose":64.55,"openAndCloseTimeList":[[1764898200000,1764907200000],[1764910800000,1764921600000]],"volumeRatio":0.5083297735250254,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02565/wiki","defaultTab":"wiki","newsList":[{"id":"1145888957","title":"一周港股牛熊榜 | 次新股量化派、云迹大涨40%以上；五矿资源飙25%持续新高；重塑能源面临解禁大跌15%；大牛股派格生物本周回落12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1145888957","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145888957?lang=zh_cn&edition=full","pubTime":"2025-12-05 18:40","pubTimestamp":1764931217,"startTime":"0","endTime":"0","summary":"值得注意的是，云迹在中国机器人服务智能体市场处于领先地位。于2024年，公司以6.3%的国内收入份额位居该市场第一。五矿资源 +25.57%得益于大宗商品特别是铜价格的持续上涨，五矿资源股价持续创新高。而大摩表示，应用仍是AI投资的首选，重申对腾讯控股、阿里巴巴和美图公司的增持评级。派格生物医药-B -12.33%大牛股派格生物医药本周出现回落。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01357","02788","00800","00376","02570","02685","01208","02670","01138","02565"],"gpt_icon":1},{"id":"2588049493","title":"每日卖空追踪 | 派格生物医药-B 12月03日卖空量成交1万股，卖空比例为3.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588049493","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588049493?lang=zh_cn&edition=full","pubTime":"2025-12-03 16:30","pubTimestamp":1764750628,"startTime":"0","endTime":"0","summary":"派格生物医药-B北京时间12月03日，涨0.55%，卖空量成交1万股，较上一交易日减少87.65%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203163446978d7ba8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203163446978d7ba8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565","BK1161"],"gpt_icon":0},{"id":"2587765920","title":"派格生物：向证监会提交H股全流通备案申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2587765920","media":"国际金融报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2587765920?lang=zh_cn&edition=full","pubTime":"2025-11-29 22:35","pubTimestamp":1764426956,"startTime":"0","endTime":"0","summary":"11月28日，派格生物医药-B(02565.HK)发布公告称，当日向中国证监会申请将20名股东持有的约26.35%未上市股份（1.017亿股）按一比一转换为H股并上市。尽管无需股东大会批准，但尚待监管审批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511293578339825.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511293578339825.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02565","BK1161"],"gpt_icon":0},{"id":"2586202061","title":"派格生物医药-B(02565)就申请建议实行H股全流通向中国证监会备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2586202061","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586202061?lang=zh_cn&edition=full","pubTime":"2025-11-28 16:45","pubTimestamp":1764319505,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派格生物医药-B(02565)发布公告，本公司已于2025年11月28日就按一比一的基准将本公司20名股东持有的合共1.02亿股未上市股份转换为本公司H股(占本公司于本公告日期已发行股份总数约26.35%)而向中国证监会提交申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","161726","02565","399441"],"gpt_icon":0},{"id":"2586297590","title":"派格生物医药-B(02565.HK)高开逾7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586297590","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586297590?lang=zh_cn&edition=full","pubTime":"2025-11-27 09:44","pubTimestamp":1764207862,"startTime":"0","endTime":"0","summary":"每经AI快讯，派格生物医药-B(02565.HK)高开逾7%，截至发稿，涨7.03%，报70港元，成交额77万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511273576346796.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511273576346796.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02565","399441","BK1161","161726"],"gpt_icon":0},{"id":"2586547062","title":"派格生物医药-B(02565)：基石投资者自愿延长禁售期","url":"https://stock-news.laohu8.com/highlight/detail?id=2586547062","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586547062?lang=zh_cn&edition=full","pubTime":"2025-11-26 20:40","pubTimestamp":1764160855,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派格生物医药-B(02565)发布公告，近日，本公司接获益泽康瑞医药(香港)有限公司(基石投资者)的通知，基石投资者同意自原禁售期届满日期起至2025年12月31日不会以任何方式减持任何相关H股(禁售延长)。本公司认为，禁售期延长表明基石投资者基于本公司对推进技术方面的研发能力及在重大临床里程碑方面取得的重大进展，对本公司的未来前景充满信心。基石投资者亦将持续审阅本公司业绩，且或会基于实时发展及所实现的里程碑，考虑进一步延长禁售期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1374112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","399441","02565","161726"],"gpt_icon":0},{"id":"2586147218","title":"每日卖空追踪 | 派格生物医药-B 11月26日卖空量成交9500股，卖空比例为1.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586147218","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586147218?lang=zh_cn&edition=full","pubTime":"2025-11-26 16:30","pubTimestamp":1764145828,"startTime":"0","endTime":"0","summary":"派格生物医药-B北京时间11月26日，涨2.51%，卖空量成交9500股，较上一交易日增加58.33%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126163432951b4ba8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251126163432951b4ba8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565","BK1161"],"gpt_icon":0},{"id":"2586499774","title":"每日卖空追踪 | 派格生物医药-B 11月24日卖空量成交4500股，卖空比例为0.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586499774","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586499774?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:30","pubTimestamp":1763973030,"startTime":"0","endTime":"0","summary":"派格生物医药-B北京时间11月24日，涨3.56%，卖空量成交4500股，较上一交易日增加350%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124163423a70de0e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251124163423a70de0e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02565"],"gpt_icon":0},{"id":"2585121009","title":"每日卖空追踪 | 派格生物医药-B 11月21日卖空量成交500股，卖空比例为0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585121009","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585121009?lang=zh_cn&edition=full","pubTime":"2025-11-21 16:30","pubTimestamp":1763713831,"startTime":"0","endTime":"0","summary":"派格生物医药-B北京时间11月21日，涨1.12%，卖空量成交500股，较上一交易日减少97.5%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112116353795124fd1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112116353795124fd1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565","BK1161"],"gpt_icon":0},{"id":"2585664601","title":"智通港股早知道 | 美国9月非农超预期 年内第三次降息恐难落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2585664601","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585664601?lang=zh_cn&edition=full","pubTime":"2025-11-21 07:40","pubTimestamp":1763682015,"startTime":"0","endTime":"0","summary":"信达生物近期计划向国家药监局递交玛仕度肽9mg用于成人体重控制的上市申请。据新华财经，美国9月季调后非农就业人口新增11.9万人，预期5万人。经济数据断供终结，但美联储立场已生变，综合数据与美联储官员言论来看，年内第三次降息恐难落地。但由于多达7家竞标方参与竞拍，价格迅速攀升。截至2025年10月，该药品累计研发投入约34.95亿元。此次纳入有望加速其审评与上市进程，但新药上市仍存不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"34d449692bfaa2931f7d79cc1f94e2b9","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1371856.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SGCmain","HK0000165453.HKD","MGCmain","BK1161","NUGT","02696","GCmain","518880","02565","SGUmain","DUST","SImain","159934","IAU","GDX"],"gpt_icon":1},{"id":"2584920925","title":"每日卖空追踪 | 派格生物医药-B 11月19日卖空量成交8000股，卖空比例为1.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584920925","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584920925?lang=zh_cn&edition=full","pubTime":"2025-11-19 16:30","pubTimestamp":1763541028,"startTime":"0","endTime":"0","summary":"派格生物医药-B北京时间11月19日，跌0.92%，卖空量成交8000股，较上一交易日减少79.22%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119163440a4ac5133&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119163440a4ac5133&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565","BK1161"],"gpt_icon":0},{"id":"2584972959","title":"强生30.5亿美元收购肿瘤新贵Halda；胃癌双抗Ziihera三期数据积极；派格生物GLP-1R激动剂“维培那肽”获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2584972959","media":"药财社","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584972959?lang=zh_cn&edition=full","pubTime":"2025-11-18 20:00","pubTimestamp":1763467253,"startTime":"0","endTime":"0","summary":"此次收购旨在进一步扩大强生在实体瘤及前列腺癌治疗领域的业务版图。2胃癌双抗Ziihera三期数据积极Jazz Pharmaceuticals与Zymeworks今日联合宣布，其3期HERIZON-GEA-01研究取得积极主要结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119001738a7024fb8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119001738a7024fb8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565","BK1161"],"gpt_icon":0},{"id":"2584878951","title":"派格生物医药-B11月18日主力净流入9.1万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2584878951","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584878951?lang=zh_cn&edition=full","pubTime":"2025-11-18 16:15","pubTimestamp":1763453746,"startTime":"0","endTime":"0","summary":"11月18日, 派格生物医药-B股价涨7.41%，报收65.20元，成交金额4829.7万元，换手率0.27%，振幅7.91%，量比2.14。派格生物医药-B今日主力资金净流入9.1万元，上一交易日主力净流出122.6万元。该股近5个交易日上涨23.11%，主力资金累计净流入48.3万元；近20日主力资金累计净流出39.1万元，其中净流出天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251118162028a70156ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251118162028a70156ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02565"],"gpt_icon":0},{"id":"2584382951","title":"派格生物医药PB-119上市申请获批，公司加快全球商业化战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2584382951","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584382951?lang=zh_cn&edition=full","pubTime":"2025-11-18 14:17","pubTimestamp":1763446620,"startTime":"0","endTime":"0","summary":"消息面上，派格生物医药近日公告，中国国家药品监督管理局已批准公司核心产品PB-119的新药上市申请。该产品为国家科技重大专项认定为“重大新药创制”的国家原创1类新药。值得一提的是，今年10月，派格生物医药宣布与阿联酋领先医药研发机构PDC FZ-LLC达成战略合作，独家授予其在中东及非洲地区开发、分销、营销及商业化派格生物的核心产品Visepegenatide 。此次合作标志着派格生物全球商业化战略迈出关键一步。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251118143211950b8c37&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251118143211950b8c37&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565","BK1161"],"gpt_icon":0},{"id":"2584983678","title":"港股异动 | 派格生物医药-B(02565)涨超5% PB-119上市申请获批 公司加快全球商业化战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2584983678","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584983678?lang=zh_cn&edition=full","pubTime":"2025-11-18 13:39","pubTimestamp":1763444395,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B涨超5%，截至发稿，涨5.11%，报63.8港元，成交额2925.59万港元。消息面上，派格生物医药近日公告，中国国家药品监督管理局已批准公司核心产品PB-119的新药上市申请。值得一提的是，今年10月，派格生物医药宣布与阿联酋领先医药研发机构PDC FZ-LLC达成战略合作，独家授予其在中东及非洲地区开发、分销、营销及商业化派格生物的核心产品Visepegenatide 。此次合作标志着派格生物全球商业化战略迈出关键一步。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1370404.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B64QTZ34.USD","BK4211","BK1161","02565","161726","PB","IE00BLDYK493.USD","399441"],"gpt_icon":0},{"id":"2584673879","title":"每日卖空追踪 | 派格生物医药-B 11月17日卖空量成交5500股，卖空比例为0.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584673879","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584673879?lang=zh_cn&edition=full","pubTime":"2025-11-17 16:30","pubTimestamp":1763368229,"startTime":"0","endTime":"0","summary":"派格生物医药-B北京时间11月17日，跌4.03%，卖空量成交5500股，较上一交易日减少72.5%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111716344095097b68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111716344095097b68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565","BK1161"],"gpt_icon":0},{"id":"2584623578","title":"派格生物医药-B11月17日主力净流出122.6万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2584623578","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584623578?lang=zh_cn&edition=full","pubTime":"2025-11-17 16:15","pubTimestamp":1763367343,"startTime":"0","endTime":"0","summary":"11月17日, 派格生物医药-B股价跌4.03%，报收60.70元，成交金额5355.1万元，换手率0.30%，振幅27.98%，量比3.98。派格生物医药-B今日主力资金净流出122.6万元，上一交易日主力净流入161.7万元。该股近5个交易日上涨13.67%，主力资金累计净流入39.2万元；近20日主力资金累计净流出48.2万元，其中净流出天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117161935976e6af3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117161935976e6af3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02565"],"gpt_icon":0},{"id":"2584623529","title":"国产长效GLP-1新贵“维培那肽”获批，派格生物涨超12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584623529","media":"中国医药创新促...","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584623529?lang=zh_cn&edition=full","pubTime":"2025-11-17 14:09","pubTimestamp":1763359775,"startTime":"0","endTime":"0","summary":"随着维培那肽获批的消息发布，派格生物尾盘涨超12%。IIIb期研究中，联合二甲双胍治疗24周，HbA1c降幅达1.27%。两项研究均显示，维培那肽低血糖事件发生率极低。2024 年，全球 GLP-1RA 市场规模达到近 500 亿美元，同比增长超过 40%。然而，在市场结构上，进口药仍占据绝对主导地位，诺和诺德在中国 GLP-1RA 市场的份额高达 80%，2024 年其在大中华地区 GLP-1RA 药物销售额约 71 亿人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117145255a6feabc3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117145255a6feabc3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565","BK1161"],"gpt_icon":0},{"id":"2584697958","title":"港股异动 | 派格生物医药-B(02565)高开近15% 核心产品PB-119新药上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2584697958","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584697958?lang=zh_cn&edition=full","pubTime":"2025-11-17 09:28","pubTimestamp":1763342919,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B高开近15%，截至发稿，涨14.94%，报72.7港元，成交额112.69万港元。消息面上，11月14日，派格生物医药-B发布公告，中国国家药品监督管理局已批准本公司核心产品PB-119的新药上市申请。该产品为国家科技重大专项认定为“重大新药创制”的国家原创1类新药。PB-119可显著改善β细胞功能，除血糖外，兼具全面管理患者的血压、血脂及体重，实现“四高共管，全面获益”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02565","IE00BLDYK493.USD","161726","BK1161","BK4211","PB","399441","IE00B64QTZ34.USD"],"gpt_icon":0},{"id":"2583663186","title":"派格生物长效 GLP-1“维培那肽”获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2583663186","media":"药事纵横","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583663186?lang=zh_cn&edition=full","pubTime":"2025-11-16 08:03","pubTimestamp":1763251394,"startTime":"0","endTime":"0","summary":"NMPA发布2025年11月14日药品批准证明文件送达信息，本批次共有129个受理号获批，其中：派格生物的维培那肽注射液获批上市，用于改善成人2型糖尿病患者的血糖控制。此外，维培那肽在降压、调脂等改善心血管危险因素方面均具有显著作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251116084057a6fc31e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251116084057a6fc31e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02565","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pegbio.com","stockEarnings":[{"period":"1week","weight":-0.1233},{"period":"1month","weight":0.1113},{"period":"3month","weight":0.4328},{"period":"6month","weight":5.5385},{"period":"1year","weight":3.0321},{"period":"ytd","weight":3.0321}],"compareEarnings":[{"period":"1week","weight":0.0087},{"period":"1month","weight":0.0058},{"period":"3month","weight":0.0262},{"period":"6month","weight":0.0964},{"period":"1year","weight":0.3336},{"period":"ytd","weight":0.3004}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"派格生物医药（杭州）股份有限公司是一家主要从事研究及开发慢性病创新疗法的中国公司。该公司的主要产品PB-119为自主开发、接近商业化阶段的长效胰高血糖素样肽1（GLP-1，一种降低血糖水平的肽类激素）受体激动剂。该公司的候选产品包括PB-718、PB-1902、PB-722、PB-2301和PB-2309。该公司的产品主要用于治疗2型糖尿病（T2DM）、肥胖症、非酒精性脂肪性肝炎（NASH）、阿片类药物引起的便秘（OIC，使用阿片类药物引起的胃肠道疾病）及先天性高胰岛素血症（一种罕见的内分泌疾病，患者持续出现低血糖症）等常见慢病及代谢疾病。","exchange":"SEHK","name":"派格生物医药-B","nameEN":"PEGBIO CO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"派格生物医药-B(02565)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供派格生物医药-B(02565)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"派格生物医药-B,02565,派格生物医药-B股票,派格生物医药-B股票老虎,派格生物医药-B股票老虎国际,派格生物医药-B行情,派格生物医药-B股票行情,派格生物医药-B股价,派格生物医药-B股市,派格生物医药-B股票价格,派格生物医药-B股票交易,派格生物医药-B股票购买,派格生物医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"派格生物医药-B(02565)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供派格生物医药-B(02565)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}